Table 1. Measurements stratifiedby LDL-TG quartile in subjectswith diabetes.
| Quartile | Total | Q1 | Q2 | Q3 | Q4 | p trend＊1 |
|---|---|---|---|---|---|---|
| LDL-TG (mg/dl) | 14.5 (6.7-59.7) a | 10.2 (6.7-11.8) | 13.3 (11.9-14.4) | 15.8 (14.5-17.3) | 20.4 (17.4-59.7) | |
| Number | 1085 | 266 | 272 | 276 | 271 | |
| Male | 680 (63%) b | 192 (72%) | 172 (63%) | 169 (61%) | 147 (54%) | ＜0.0001 |
| Age (y) | 67.0 (11.1) c | 67.5 (10.2) | 67.0 (10.7) | 66.5 (12.0) | 66.9 (11.4) | ns |
| Current smoker | 183 (17%) | 35 (13%) | 46 (17%) | 53 (19%) | 49 (18%) | ns |
| Alcohol drinke | 382 (35%) | 94 (35%) | 89 (33%) | 96 (35%) | 103 (38%) | ns |
| Coronary heart disease | 117 (11%) | 32 (12%) | 33 (12%) | 29 (11%) | 23 (8%) | ns |
| Cerebelovascular disease | 91 (8%) | 22 (8%) | 20 (7%) | 26 (9%) | 23 (8%) | ns |
| Type 1 diabetes | 27 (3%) | 8 (3%) | 5 (2%) | 6 (2%) | 8 (3%) | ns |
| Insuilin | 232 (21%) | 54 (20%) | 54 (20%) | 65 (24%) | 59 (22%) | ns |
| insulin dose (U) | 23 [15-33] d | 22 [14-34] | 23 [16-32] | 24 [16-32] | 22 [16-34] | ns |
| Hypotensive drugs | 645 (59%) | 157 (59%) | 164 (60%) | 154 (56%) | 170 (63%) | ns |
| Hypolipidemic drugs | 681 (63%) | 158 (59%) | 189 (69%) | 161 (58%) | 173 (64%) | ns |
| Statins | 597 (55%) | 149 (56%) | 176 (65%) | 140 (51%) | 132 (49%) | 0.0076 |
| Fibrates | 75 (7%) | 5 (2%) | 10 (4%) | 19 (7%) | 41 (15%) | ＜0.0001 |
| SBP (mmHg) | 132 (14) | 130 (14) | 131 (13) | 133 (15) | 134 (14) | 0.0426 |
| BMI (Kg/m2) | 25.2 (4.2) | 24.4 (3.7) | 25.2 (4.0) | 25.5 (4.3) | 25.7 (4.7) | 0.0051 |
| Fatty liver＊2 | 130 (49%) | 21 (37%) | 33 (49%) | 37 (52%) | 39 (55%) | 0.0439 |
| VFA (cm2)＊3 | 159.2 (81.2) | 148.1 (63.6) | 156.1 (80.6) | 157.5 (82.0) | 174.4 (94.8) | ns |
| ALT (U) | 20 [15-30] | 18 [15-25] | 22 [15-32] | 20 [15-29] | 21 [15-34] | ns |
| γGTP (U) | 25 [17-42] | 21 [16-32] | 25 [18-40] | 25 [17-42] | 30 [18-58] | ＜0.0001 |
| HbA1c (%) | 7.4 (0.9) | 7.3 (0.7) | 7.4 (0.9) | 7.5 (0.9) | 7.4 (1.0) | ns |
| Glucose (mg/dL) | 149 (39) | 145 (33) | 150 (39) | 148 (38) | 153 (47) | ns |
| C-peptide (mg/dL) | 1.3 [0.8-1.9] | 1.2 [0.8-1.6] | 1.4 [0.9-2.0] | 1.3 [0.8-1.8] | 1.4 [0.9-2.1] | 0.0416 |
| TC (mg/dL) | 182 (31) | 172 (27) | 174 (28) | 185 (29) | 195 (34) | ＜0.0001 |
| TG (mg/dL) | 104 [76-149] | 87 [66-121] | 104 [78-151] | 106 [74-153] | 117 [93-177] | ＜0.0001 |
| %LDL-TG/TG | 13.9 [9.5-19.6] | 11.6 [8.2-15.3] | 12.6 [8.9-16.8] | 14.9 [10.5-21.2] | 18.2 [12.1-22.7] | ＜0.0001 |
| LDL-C (mg/dL) | 102 (24) | 93 (22) | 98 (21) | 105 (23) | 112 (26) | ＜0.0001 |
| %LDL-TG/LDL-C | 14.4 (11.9-18.0) | 11.0 (9.2-12.9) | 13.5 (11.7-15.7) | 15.1 (13.1-17.7) | 19.0 (16.2-23.2) | ＜0.0001 |
| HDL-C (mg/dL) | 54 (14) | 56 (14) | 53 (14) | 55 (15) | 53 (14) | ns |
| NonHDL-C (mg/dL) | 127 (28) | 115 (23) | 121 (24) | 130 (26) | 142 (31) | ＜0.0001 |
| lbLDL-C (mg/dL) | 71 (21) | 67 (19) | 69 (18) | 74 (21) | 73 (23) | 0.0001 |
| sdLDL-C (mg/dL) | 28.0 [21.3-38.1] | 23.5 [18.2-30.8] | 27.7 [20.7-34.5] | 28.9 [22.2-37.0] | 35.5 [25.0-50.1] | ＜0.0001 |
| TRL-C (mg/dL) | 23 [18-29] | 21 [17-25] | 22 [17-28] | 23 [18-30] | 27 [20-35] | ＜0.0001 |
| apoB (mg/dL) | 87 (18) | 78 (15) | 84 (15) | 89 (16) | 99 (21) | ＜0.0001 |
| apoCIII (mg/dL) | 10.4 (8.3-12.9) | 10.0 (8.0-12.0) | 10.1 (8.4-12.5) | 10.4 (8.5-12.7) | 11.2 (8.7-14.1) | 0.0002 |
| apoE (mg/dL) | 4.1 (1.3) | 3.8 (1.2) | 3.9 (1.1) | 4.1 (1.2) | 4.6 (1.4) | ＜0.0001 |
| Lp (a) (mg/dL) | 13.1 [6.2-24.8] | 11.7 [5.7-22.6] | 15.0 [6.6-25.5] | 12.7 [6.2-23.1] | 12.8 [6.1-31.6] | ns |
| eGFR (ml/min/1.73m2) | 70.9 (20.0) | 71.0 (18.3) | 70.1 (20.8) | 72.1 (19.5) | 70.2 (21.3) | ns |
| UAR (mg/g) | 16.2 [6.8-51.7] | 13.8 [5.4-49.9] | 16.5 [7.2-54.0] | 14.0 [6.1-36.4] | 19.9 [8.2-74.4] | ns |
| WBC | 6583 (1714) | 6131 (1567) | 6590 (1513) | 6654 (1785) | 6950 (1871) | ＜0.0001 |
| hsCRP (ng/L) | 0.06 [0.03-0.13] | 0.03 [0.02-0.07] | 0.05 [0.03-0.12] | 0.07 [0.03-0.15] | 0.09 [0.04-0.21] | ＜0.0001 |
a): median (total range) b): n (%) c): mean (SD) d): median [IQR]
＊1 The p trend was estimated by Cochran-Armitagetrend test for categoricalvariablesor Jonckheere-Terpstratrend test for continuous variables.
＊2 Total 267 subjects were measured Fatty liver.
＊3 Total 195 subjects were measuredVFA.